<?xml version="1.0" encoding="UTF-8"?><rss xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:atom="http://www.w3.org/2005/Atom" version="2.0"><channel><title><![CDATA[Hansa Biopharma — August 2025]]></title><description><![CDATA[<p dir="auto"><a href="https://mb.cision.com/Main/1219/4213760/3597851.pdf" rel="nofollow ugc">https://mb.cision.com/Main/1219/4213760/3597851.pdf</a> Hansa Biopharma announces supportive data from treatment with imlifidase prior to the administration of gene therapy for Duchenne muscular dystrophy</p>
]]></description><link>https://dev.proinvestor.com/forum/topic/400765/hansa-biopharma-august-2025</link><generator>RSS for Node</generator><lastBuildDate>Sat, 06 Jun 2026 04:09:51 GMT</lastBuildDate><atom:link href="https://dev.proinvestor.com/forum/topic/400765.rss" rel="self" type="application/rss+xml"/><pubDate>Fri, 01 Aug 2025 19:20:02 GMT</pubDate><ttl>60</ttl></channel></rss>